Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey

European Journal of Pediatrics

Volumn 166, Issue 6, 2007, Pages 533-539

  Soysal, Ahmet ^a   Gokçe, Ibrahim ^a   Pehlivan, Tamer ^b   Bakir, Mustafa ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Children; Hepatitis A vaccine; Immunogenicity; Interchangeability; Safety; Seroprevalence

Indexed keywords

HEPATITIS A VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ANTIBODY TITER; ARTICLE; ASTHENIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNE RESPONSE; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; SEROLOGY; SEROPREVALENCE; SKIN INDURATION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HUMANS; INFANT; MALE; SEROEPIDEMIOLOGIC STUDIES; TURKEY;

EID: 34247357770     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-007-0432-0     Document Type: Article

References (35)

1. Abarca K, Ibanez I, Perret C, Vial P, Zinsou J-A (2004) Immunogenicity and safety of Avaxim 80U-Pediatric and Havrix 720 in Chilean children from 1 to 15 years of age. Int J Infect Dis 8(Suppl 1):S18
2. Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Gluck R, Herzog C (1997) Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15(11):1209-1213
3. Atabek ME, Fyndyk D, Gulyuz A, Erkul I (2004) Prevalence of anti-HAV and anti-HEV antibodies in Konya, Turkey. Health Policy 67(3):265-269
4. Bell BP (2002) Hepatitis A vaccine. Sem Pediatr Infect Dis 13 (3):165-173
5. Bell BP, Feinstone SM (2004) Hepatitis Avaccine. In: Plotkin SA, Orenstein WA (eds) Vaccine, 4th edn. Saunders, Philadelphia, Pennsylvania, pp 269-297
6. Bryan JP, Henry CH, Hoffman AG, South-Paul JE, Smith JA, Cruess D, Spieker JM, de Medina M (2000) Randomized, crossover, controlled comparison of two inactivated hepatitis A vaccine. Vaccine 19(7-8):743-750
7. Castillo de Febres O, Chacon de Petrola M, Casanova de Escalona L, Naveda O, Naveda M, Estopinan M, Bordones G, Zambrano B, Garcia A, Dumas R (1999) Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine 18(7-8):656-664
8. Dagan R, Greenberg D, Goldenbertg-Gehtman P, Vidor E, Briantais P, Pinsk V, Athias O, Dumas R (1999) Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine 17(15-16):1919-1925
9. Dagan R, Greenberg D, Weber F (2005) Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine 23(44):5144-5148
10. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D (2005) Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294(2):202-210
11. Dominguez A, Bruguera M, Plans P, Costa J, Salleras L (2004) Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization. J Med Virol 73(2):172-176
12. Erdogan MS, Otkun M, Tatman-Otkun M, Akata F, Ture M (2004) The epidemiology of hepatitis Avirus infection in children, in Edirne, Turkey. Eur J Epidemiol 19(3):267-273
13. Franco E, Giambi C, Ialacci R, Maurici M (2003) Prevention of hepatitis A by vaccination. Expert Opin Biol Ther 3(6):965-974
14. Hollinger FB, Ticehurst JR (1996) Hepatitis A virus. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, 3rd edn. Lippincott-Raven, Philadelphia, Pennsylvania, pp 735-782
15. Hoppenbrouwers K, Kanra G, Roelants M, Ceyhan M, Vandermeulen C, Yurdakök K, Silier T, Dupuy M, Pehlivan T, Özmert E, Desmyter J (1999) Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine 17(7-8):875-886
16. Kanra G, Tezkan S, Badur S; Turkish National Study Team (2002) Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr 44(3):204-210
17. Koff RS (1992) Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 10(Suppl 1):S15-S17
18. Koff RS (1998) Hepatitis A. Lancet 351(9116):1643-1649
19. Lemon SM (1985) Type A viral hepatitis. New developments in an old disease. N Engl J Med 313(17):1059-1067
20. Lemon SM, Murphy PC, Provost PJ, Chalikonda I, Davide JP, Schofield TL, Nalin DR, Lewis JA (1997) Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. J Infect Dis 176(1):9-19
21. Lolekha S, Pratuangtham S, Punpanich W, Bowonkiratikachorn P, Chimabutra K, Weber F (2003) Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in Thai children: comparison of three vaccination schedules. J Trop Pediatr 49 (6):333-339
22. Lopez EL, Del Carmen Xifro M, Tarrado LE, De Rosa MF, Gomez R, Dumas R, Wood SC, Contrini MM (2001) Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 20(1):48-52
23. MacIntyre CR, Burgess MA, Hull B, McIntyre PB (2003) Hepatitis A vaccination options for Australia. J Paediatr Child Health 39(2):83-87
24. Ministro de Salud y Ambiente (2005) Comenzó la vacunción gratuita contra la hepatitis A en todo el pais. Available online at http://www.msal.gov.ar/htm/site/Noticias_plantilla.asp?Id=569
25. Scheifele DW (2005) Hepatitis A vaccines: the growing case for universal immunisation of children. Expert Opin Pharmacother 6 (2):157-164
26. Sidal M, Ünüvar E, Oguz F, Cihan C, Önel D, Badur S (2001) Age-specific seroepidemiology of hepatitis A, B, and E infections among children in Istanbul, Turkey. Eur J Epidemiol 17(2):141-144
27. Tosun S, Ertan P, Kasirga E, Atman Ü (2004) Changes in seroprevalence of hepatitis A in children and adolescents in Manisa, Turkey. Pediatr Int 46(6):669-672
28. Ungan M, Yaman H, Taheri N (2002) The prevalence of antibodies to hepatitis A among preschool children in an urban setting in Turkey. J Trop Pediatr 48(3):180-182
29. Van Herck K, Van Damme P (2005) Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 4(4):459-471
30. Vidor E, Dumas R, Porteret V, Bailleux F, Veitch K (2004) Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis 23(4):300-309
31. Vidor E, Xueref C, Blondeau C, Bajard A, Françon A, Goudeau A, Peyron F, Brasseur P, Zuckerman A (1996) Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine. Biologicals 24(3):235-242
32. WHO (2000) WHO position paper on hepatitis A vaccines. Wkly Epidemiol Rec 75:37-44
33. Wiedmann M, Boehm S, Schumacher W, Swysen C, Zauke M (2003) Evaluation of three commercial assays for the detection of hepatitis A virus. Eur J Clin Microbiol Infect Dis 22(2):129-130
34. Yapicioglu H, Alhan E, Yildizdas D, Yaman A, Bozdemir N (2002) Prevalence of hepatitis A in children and adolescents in Adana, Turkey. Indian Pediatr 39(10):936-941
35. Zuckerman JN, Kirkpatrick CT, Huang M (1998) Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against Hepatitis A. J Travel Med 5(1):18-22